Detection of Genetic Markers of Lung Cancer
The purpose of this research study is to determine the genetic changes and immunologic changes that are involved in the development and progression of bronchogenic lung cancer.
Checked against the public recordLast updated Oct 24, 2025 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- University of Pittsburgh
- Interventions being studied
- Procedure: Biopsy of the major carinal area; Procedure: Biopsy of abnormal & suspicious areas of the bronchial tree; Procedure: Evaluation of the tumor for DNA mutations; Procedure: Bronchoalveolar Lavage (BAL) for cytokine analysis; Procedure: Correlation of flow cytometric & RT PCR for TNM stage; Procedure: Analysis of lymph nodes
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Histologic confirmation of lung cancer, lung metastases from a primary site other than lung, mesothelioma or a radiographic lesion highly suspicious for malignancy * Written informed consent. * To be scheduled for a biopsy or surgical resection or have already had a biopsy and/or surgical removal of a lung mass Exclusion Criteria: None
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Hillman Cancer CenterPittsburgh, Pennsylvania
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 24, 2025. Always confirm current availability with the study team.